UNSPSC 51282322: Erythromycin lactobionate

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C12H22O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33H58I7GLQ, chemically known as erythromycin, n-demethyl-n-(methyl-11c)- but more generally known as erythromycin lactobionate, which bears US NIH Compound Identifier 12560. European Medicines Agency schedules Erythromycin lactobionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01944MIG.

Most nations, for tariff and trade purposes, schedule erythromycin lactobionate under HS 29415000 and SITC 54139. Erythromycin lactobionate bears US NLM identifiers UMLS ID C0059562 and NCI Concept Code C47988. SMILES: As of Q4 2014, ERYTHROMYCIN LACTOBIONATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51282322 Erythromycin lactobionate, a Commodity code, shows limited recent state and local procurement activity aligned with its specific pharmaceutical scope. The recent opportunities tagged to this code involve medical and pharmaceutical supplies more broadly—naloxone and drug deactivation systems, first-aid equipment, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs—rather than erythromycin lactobionate specifically. State and local buyers under this code include county health departments, city fire and rescue divisions, cooperative purchasing alliances serving multiple state and local entities, and state health and human services agencies procuring on behalf of employee and program populations.

Recent activity spans Florida, Texas, and Minnesota-led cooperative purchasing. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and safe drug deactivation systems for community health initiatives with quarterly deliveries. The City of Tampa issued an IFB (26P00145, due March 13, 2026) for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00 and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) to explore direct-to-manufacturer prescription programs for state pharmacy benefit management. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon, with awarded vendors taking effect July 1, 2026. The code itself appears underutilized for erythromycin lactobionate procurement; opportunities tagged to it reflect broader pharmaceutical and medical supply buying patterns rather than this specific antibiotic product line.